《Gut》上的一项新研究报告了晚期肝癌（HCC）患者的免疫系统T细胞对肿瘤的反应。

Anew study published in the scientific journal Gut examines how immune system T cells respond to tumours in patients with advanced liver cancer (HCC).

利用Neogap Therapeutics的PIOR®软件平台，研究人员已经确定了肿瘤特异性突变，这可能有助于个性化免疫疗法的发展。

Using Neogap Therapeutics' PIOR® software platform, the researchers have identified tumour-specific mutations, which may contribute to the development of personalised immunotherapies.

T细胞是人体防御癌症的核心，但也有助于肿瘤内的免疫抑制环境。

T cells are central to the body's defence against cancer but can also contribute to an immunosuppressive environment within the tumour.

该研究分析了来自肝脏、淋巴结和肿瘤组织的T细胞，以确定对癌症相关的新抗原反应最活跃的细胞，新抗原是通过突变形成的肿瘤特异性蛋白质，可以激活免疫系统。

The study analysed T cells from the liver, lymph nodes, and tumour tissue to identify the most reactive cells to cancer-related neoantigens—tumour-specific proteins formed through mutations that can activate the immune system.

生物信息学分析从7名患者中鉴定出542种潜在的新抗原，其中14种被发现能诱导强烈的免疫反应，特别是在肝脏和淋巴结的T细胞中。

Bioinformatic analysis identified 542 potential neoantigens from seven patients, 14 of which were found to induce a strong immune response, particularly in T cells from the liver and lymph nodes.

通过使用PIOR®，研究人员能够识别能够激活T细胞的新抗原，T细胞反过来可以攻击肿瘤。

By using PIOR®, the researchers were able to identify neoantigens capable of activating T cells, which in turn can attack the tumour.

结果表明，PIOR®可以有效地识别具有未来治疗应用潜力的新抗原。

The results demonstrate that PIOR® can effectively identify neoantigens with potential for future therapeutic applications.

数据驱动的新抗原分析是新一代个性化癌症免疫疗法的重要组成部分。

Data-driven analysis of neoantigens is an important component of the new generation of personalised cancer immunotherapies.

研究结果表明，来自肝脏和淋巴结的T细胞具有特别适合未来免疫疗法的特性。

The findings show that T cells from the liver and lymph nodes have properties that may be particularly suitable for future immunotherapies.

这项研究为T细胞对新抗原的反应提供了更深入的见解。

The study provides deeper insights into how T cells respond to neoantigens.

Original publication

Panagiota Maravelia, Haidong Yao, Curtis Cai, Daniela Nascimento Silva, Jennifer Fransson, Ola B Nilsson, Yong-Chen William Lu, Patrick Micke, Johan Botling, Francesca Gatto, Giulia Rovesti, Mattias Carlsten, Matti Sallberg, Per Stål, Carl Jorns, Marcus Buggert, Anna Pasetto; "Unlocking novel T cell-based immunotherapy for hepatocellular carcinoma through neoantigen-driven T cell receptor isolation"; Gut, 2025-1-19

Topics